Pharma Journalist

PURIFY’23
2023-11-07 | ITC KOHENUR, HYDERABAD, INDIA
PURIFY – Chromatography Purification Conclave
PURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities, be it discovery, development or scaleups!
The pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification.
The attendees at PURIFY get exposed to a myriad of topics that could change the way they work…change the way they purify. New separation techniques and approaches, niche topics, deeper understanding of preparative and process chromatography and allied fields, and upcoming application areas that will provide quality substance to the discerning scientists. So, if you wish to get that additional gram, which is purer, in as less a time, with minimal resources…there will surely be something for you at PURIFY conclaves!
The annually occurring PURIFY Conclave is an initiative by Custage Marketing Solutions LLP, a Mumbai based company.
The PURIFY conclave is attended by analytical and research chemists, scientists with scale-up and process development knowledge, managers, group heads, natural product purification experts, experts from quality and manufacturing, academicians, policy makers, supply chain heads etc. of this pharmaceutical – APIs, peptides, proteins, oligonucleotides, chiral molecules, bio-pharmaceutical, fine chemicals, environmental studies, food and beverage, polymers, biotechnology, cosmetics and fragrance to understand the advancements in chromatography platforms.
So, the purification expert in you will surely get answers to the daily challenges faced for you in your laboratories. And what’s more, the knowledge comes to you from dignitaries who are institutions on their own in chromatography purification and related.
To know more visit: https://www.purifyconclaves.com/

7th Microbiome Movement – Human Nutrition Summit
2023-11-07 - 2023-11-09 | Westminster Hotel, 550 W Mt Pleasant Ave, Livingston, NJ, 07039, United States
The 7th Microbiome Movement – Human Nutrition Summit will unite 100+ human nutrition leaders this November in Livingston, NJ to optimize product development and consumer acceptance of microbiome-based food and nutritional products. Join the only industry led meeting dedicated to moving the needle on scientifically validated, microbiome modulating, nutritional product development.
From developing pre-, pro-, or post-biotics, functional food, microbiome modulating ingredients, to other interventions that provide microbial-mediated health benefits, this meeting offers unrivalled opportunities for those working in the microbiome human nutrition space.
Join us in Livingston, NJ, this November to hear invaluable insights from the likes of Bifidice, Danone, Holobiome, ADM, Immune Biome, and more!
View the full event guide here: https://ter.li/2ppxtz
Offering earlybird rates, exclusive group discounts and a brand-new, post-conference consumer focus day, now is the time to register. Don’t miss out, secure your place now: https://ter.li/8algsb

5th Annual Gene Therapy Analytical Development Summit 2023
2023-11-27 - 2023-11-30 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
Behind regulatory milestones like the recent accelerated FDA approval for Duchenne Muscular Dystrophy, robust and detailed analytics are the cornerstone of gene therapy development. As regulators scrutinize products more closely, accurately characterizing gene therapy products and standing behind safety and efficacy is crucial to drug developers bringing gene therapies into and through the clinic.
In this context, the 5th Annual Gene Therapy Analytical Development is returning in 2023, uniting 400+ analytical experts to explore how the latest analytical methods are being developed and applied to guarantee the quality, consistency, safety, and efficacy of gene therapy products.
Join biopharma colleagues specializing in bioassays, molecular biology, physicochemical properties, quality, process development and regulation across 4 days of niche, expert presentations, and dedicated networking opportunities. This is your must-attend meeting to collaborate ideas, success and challenges to capitalize on the technological advances in analytical development to reach the ultimate goal of bringing safer, efficacious therapies to patients more quickly and effectively.
To know more visit: https://ter.li/qf50s3

7th Obesity & NASH Drug Development Summit
2023-11-27 - 2023-11-29 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
Eli Lilly’s ‘triple G’ drug retatrutide has galvanized the metabolic field to boost investment in the game-changing obesity drug revolution. With up to 24% weight loss, a new record for the obesity field has been set and the time to get ahead of the curve is now. In parallel, we’re witnessing history being made with the world’s first approved NASH treatment potentially being right around the corner with Madrigal’s THR β-selective agonist, marking this year a pivotal time for the metabolic field to forever elevate the approach towards drug development and overcome regulatory barriers.
Reuniting metabolic experts to enable the assessment of the competitive landscape, the 7th Obesity & NASH Drug Development Summit is uniquely positioned to capture all the latest breakthroughs and research you need to join the race and commercialize your GLP-1 RAs, tri-agonists, dual agonists, tetra-specific drugs, glucocorticoid receptor modulators and more.
2023 is an exciting year due to the evolution in digital pathology, artificial intelligence, omics, multifunctional molecules, non-invasive biomarkers, target discovery and liver models, this is your timely meeting dedicated to bringing the metabolic community closer to navigate the route to even more approvals. However, as industry gets closer to successes, challenges remain.
Keen to overcome these discovery, regulatory, clinical, and commercial hurdles?
Join 160+ experts at the largest gathering of obesity and NASH industry drug developers from Eli Lilly, Novo Nordisk, Madrigal, Akero, Gilead, Pfizer, AstraZeneca, Gilead, Inventiva and many more to cultivate sustainable weight-loss drugs and navigate the route towards the first approval in NASH. Don’t miss your opportunity to hear from 42+ metabolic experts over 3 jam-packed days with all the latest end-to-end updates to advance your drug development.
To know more visit: https://bit.ly/465Aa3m

Cell Therapy for Autoimmune Disease Summit
2023-11-28 - 2023-11-30 | Sonesta Philadelphia Rittenhouse Square, 1800 Market Street, Philadelphia, PA, 19103, United States
Enter the inaugural Cell Therapy for Autoimmune Disease Summit, a pioneering platform singularly focused on uniting and empowering this community for the first time. Experts will delve into cutting-edge frontiers of pre-clinical, translational, and clinical advancements encompassing all cell-based therapies, including CAR-T, Treg, and MSC, with the shared objective of developing better therapies for patients with chronic autoimmune diseases.
Don’t miss out on your opportunity to network with 80+ key opinion leaders including Cabaletta Bio, Kyverna Therapeutics, AstraZeneca, Quell Therapeutics, Novartis, and more. Learn more – https://ter.li/6xwjrk

Donor Selection & Cell Source Summit 2023
2023-11-28 - 2023-11-30 | The Clift Royal Sonesta, 495 Geary Street, San Francisco, CA, 94102, United States
The Donor Selection & Cell Source Summit is your ultimate platform to explore the latest global regulatory requirements and differences on donor testing, understand the novel genome sequencing data being used to inform donor selection, and forge new partnerships to ease logistical coordination with donation sites to ensure exclusive availability of selected donor pools.
Join Senti Biosciences, Poseida Therapeutics, Caribou Bio, Allogene and more to advance your knowledge on donor selection, management and sustainability to ensure a consistent and reliable supply of cell source material required for clinical trials and beyond.
Download a copy of the event guide to view the 3-day jam-packed agenda, expert speaker faculty and exclusive pre-conference workshop day: https://ter.li/t81hko

4th Annual CRISPR 2.0 Congress 2023
2023-11-28 - 2023-11-30 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
CRISPR represents the next frontier in the cell and gene therapy landscape. Spearheaded by the first gene edited therapeutic awaiting FDA approval, a mounting wave of innovative technology developments and therapeutic applications are leading to a paradigm shift in our global healthcare systems.
To this end, the 4th Annual CRISPR 2.0 Congress is your definitive guide to showcasing the latest and greatest CRISPR tools being developed and applied in the therapeutic setting.
To know more visit: https://ter.li/rqwuyn

Advanced Purification for Complex Biologics Summit
2023-11-28 - 2023-11-30 | Sonesta Philadelphia Rittenhouse Square, 1800 Market Street, Philadelphia, PA, 19103, United States
The Advanced Purification for Complex Biologics Summit is the first and only standalone conference focused on purification for biologics and novel modalities bringing together purification, CMC and MSAT professionals to collaborate and remove purification bottlenecks to meet market delivery timelines.
This in-depth 3-day event will feature the latest breakthroughs and cutting-edge content in AI and digital learning tools to help you save time during downstream processing and boost efficiency.
This is your unique opportunity to meet 60+ purification and downstream processing experts including Sanofi, Takeda, Eli Lilly, AstraZeneca and Regeneron as they talk you through machine learning, predictive modelling, and consumables advancements to empower your process optimization, moving a step closer to 100% product purity.
To know more visit: https://ter.li/80pxjz

3rd ADC Target Selection Summit
2023-12-05 - 2023-12-07 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
The 3rd ADC Target Selection Summit (December 5-7 | Boston, MA). This is the ultimate cover-to-cover conference providing insights to help you optimize the pairing of target, antibody, and linker-payload and develop the next generation of clinically successful ADCs beyond HER2 and TROP2.
See the full program here.
As the number of new clinical ADC targets continues to increase, this year’s meeting will have a greater focus on identifying and validating novel targets, re-examining what makes a good target, and delving into the use of proteomics to ensure you get the first step of drug development right.
Here are some of the agenda highlights you cannot afford to miss:

Join Cancer Research Horizons to learn “Overcoming Hurdles in Validating Novel Targets for Clinically Applicable ADCs” and hear how an unbiased proteomics approach with patient samples was used to discover a clinically relevant ADC target for multiple myeloma
Hear from Ziel Bio on “Discovering Cell Surface Plectin: A Highly Promising Target for Multiple Solid Tumors” to understand how the hypothesized function of plectin highlights it as a good ADC target, and learn how ZB131 can selectively bind to CSP improving internalization and minimizing off-target effects
Gain insights from AstraZeneca on “A Case Study on Utilizing Hindsight Following Progression of an ADC With a HER2 Target Into the Clinic” highlighting the target selection process and reasons behind the choice of pursuing HER2, target and antibody considerations; and emphasizing challenges and successes in the use of this target for ADCs to help you prepare for your development.

Take a look at the full speaker faculty and session details.
Uniting 100+ of your peers working in biology, discovery and oncology research, this unique forum will provide you with an exclusive opportunity to learn and network with other ADC developers who are living and breathing targets all in one room.

3rd Applied Biocatalysis Summit
2023-12-05 - 2023-12-07 | The Study at University City, 20 S 33rd Street, Philadelphia, PA, 19104, United States
Enzyme Engineering Enabling Scalable Industrial Biotransformation for Sustainable API Production
In 2023, an era of advanced enzyme engineering technology is rapidly enabling the generation of game-changing enzymes for novel transformations. As witnessed for Merck’s Islatravir and BMS’ ERED/KRED biocatalytic cascade recognition, industries are fast transitioning towards biocatalysis to capitalize on more sustainable means of synthesis. The 3rd Applied Biocatalysis Summit is your must-attend meeting dedicated to accelerating enzyme discovery and reaction route development, through to scaling process chemistry for industrial applications.
With unmissable case studies from the likes of Merck, Amgen, Sanofi, Biogen, GSK, and Pfizer, this is the definitive forum to benchmark and learn with this forward-thinking community who reunite once more.
These industry titans have collaborated to form a comprehensive, 3-day program covering key topics including:

Gaining valuable insights on chemoenzymatic catalysis research, combining heterogeneous and homogeneous catalysis and making valued functionality using biocatalysis, in water with Bruce Lipshutz, Professor of Chemistry, University of California, Santa Barbara
Learn how new technologies are adding efficiencies to biocatalysis’ adoption, including AI/ML approaches, improved screening for reaction prediction & new chemistry discoveries with Merck & Pfizer
Engage in dynamic panel discussions addressing how cross-departmental collaboration enable the faster assessment and introduction of enzymatic catalysed reactions as early as possible with AbbVie, Biogen & Neorocrine Biosciences

Don’t miss this opportunity to join trailblazers and accelerate enzyme discovery and engineering, discover carbon footprint-reducing reactions and refine your process scaling strategies.

Covalent Drug Discovery Summit
2023-12-12 - 2023-12-14 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
Bringing the covalency field under one roof for the first time, the inaugural Covalent Drug Discovery Summit comes to Boston this December – gathering 80+ covalent drug specialists from the likes of Amgen, Revolution Medicines, Novartis, Totus Medicines, Covant Therapeutics and more.
This is a unique opportunity to network with an audience of CXOs, VPs, Directors and Heads of Discovery, Medicinal and Biological Chemistry focused on covalent drug discovery.
Hear from 20+ industry leaders across three days of carefully curated content, engage in dedicated networking time with the field, ask your burning questions to our expert speakers at the end of each presentation, and dive deep into two interactive workshops on toxicity and safety concerns and the future of covalency.
Download your copy of the program here to find out more: https://ter.li/z6hwj6

6th RNA-Targeted Drug Discovery & Development Summit
2023-12-12 - 2023-12-14 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
200+ Attendees | 33+ World-Class Speakers | 23+ Data Driven Case Studies
Returning to Boston this December for its 6th year, the RNA-Targeted Drug Discovery & Development Summit is the only industry-dedicated forum solely focused on small molecules targeting RNA, with a core focus on improving selectivity and specificity to enable safe and effective drugs into the clinic.
View the program here: https://ter.li/xq2eye
2023 has seen advances in artificial intelligence, screening tools and progression into the clinic, coupled with numerous strategic collaborations and investments into early discovery.
Bringing together 33+ experts presenting the latest data and case studies straight from the lab, alongside senior decision makers discussing key breakthroughs and strategy, this year’s meeting is a must-attend if you are looking to turbocharge discovery and development of small molecules targeting RNA.
Register here: https://ter.li/r67ejq

Health Economics & Outcomes Research Summit
2023-12-12 - 2023-12-14 | Wyndham Philadelphia Historic District, 400 Arch Street, Philadelphia, PA, 19106, United States
The Health Economics & Outcomes Research Summit is a focused intimate gathering of HEOR professionals, moving past basic introductions to advanced tactical and strategic conversations best leveraging innovative methods to demonstrate the value proposition of new drugs to secure formulary and market access.
Hear cutting-edge case studies into evidence generation, modeling and real-world evidence across oncology, neurology, cardiovascular, rare diseases, and beyond. Explore how leading pharma and pioneering biotechs are navigating this changing landscape including:

Adapting value assessments for evolving reimbursement requirements
Adjusting to price control mechanisms implemented by the Inflation Reduction Act
Leveraging advances AI to revolutionize data-driven decision-making

Join this gathering of HEOR experts and gain strategic and commercial market intelligence by exploring how thought leaders are redefining a robust strategy to demonstrate the clinical effectiveness, safety, and cost-effectiveness of new drugs, don’t miss out on your opportunity to fortify a resilient decision-making framework.
To know more visit: https://bit.ly/3PTp5M4

8th Oncolytic Virotherapy Summit 2023
2023-12-12 - 2023-12-14 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
Following recent struggles in the industry, the leading annual 8th Oncolytic Virotherapy Summit returns to Boston, MA in December (12-14), as the industry’s definitive, and most comprehensive forum. Bringing you 29+ world-class speakers, 10+ hours of networking, 2-panel discussions, 1 pre-conference focus day & more. This event will be showcasing brand-new pivotal data to ensure a pathway of success for regulatory approval of OV drugs.
3 days of carefully curated sessions will gather 100+ OV trailblazers across sessions spanning Early Discovery, Translation, Clinical Development, Chemistry, Manufacturing & Controls (CMC), and Regulations to overcome the industry’s largest and critical bottlenecks. Here is just a snapshot of our world-class speaker line-up who will be showcasing their expertise and critical updates:

Richard Dambra, Scientist, Viral Platforms, Boehringer Ingelheim
Francesca Barone, CSO, Candel Therapeutics
Michael Franti, Director, Viral Platform Drug Metabolism & Pharmacokinetics, Boehringer Ingelheim
Paul Hallenbeck, Chief Scientific Officer, Seneca Therapeutics
Talia Biran, President Clinical Development Operations, Oncolys

This year’s edition brings highly promising content such as the exclusive Innovation Showcase, a whole day dedicated to Clinical Design & Manufacturing Strategies and a must-attend Investor Panel from experts in Biopharma.
As the only and longest established end-to-end OV-focused conference, this is a crucial date in the industry calendar you cannot afford to miss.
To know more visit: https://ter.li/1ag3m6

Gene Therapy Process Development Summit
2023-12-13 - 2023-12-14 | Le Meridien Philadelphia, 1421 Arch Street, Philadelphia, PA, 19102, United States
The inaugural Gene Therapy Process Development Summit is a must-attend to discover the latest insights to bridge the gap between R&D and process development, ensuring that high-quality gene therapies are manufactured repeatably, at scale, and in a cost-effective manner.
Join us in Philadelphia to discover and learn the latest insights through case study presentations, informative panel discussions, and deep-dive workshops from Ultragenyx, REGENXBIO, Janssen, Amgen, Astellas Gene Therapies, and many more!
Whether you are looking to improve your platform processes or shorten development timelines this summit will be a unique opportunity to meet and network with peers to discuss successes and challenges in your process development journeys.
Join your peers to:

Learn how to achieve the ideal complex size with Meira GTx by using automation and process analytical tools to optimize transient transfection leading to enhanced efficiency, time saving and scale-up insights
Deep dive into enhancing the Pinnacle PCL Platform 2000L batch process with Ultragenyx to increase yield, improve product quality and reduce time-to-clinic
Examine case study results with Astellas Gene Therapies and explore the optimization techniques to cut costs and streamline tech transfer and scale-up times
Explore the design principles for creating robust AAV producer cell lines to yield a stable and consistent AAV production to optimize AAV vector generation to improve your platform processes with Lacerta and REGENXBIO
Unpick the ever-changing, complex regulations surrounding the world of gene therapy in a detailed workshop that doubles down on development strategies that are adaptable to the challenges by gene therapy to prevent regulatory roadblocks when trying to get drugs to clinic

Download the full agenda here to see our full speaker faculty, 2-day agenda and audience breakdown: https://ter.li/nxp0nz

Pre-Filled Syringes and Injectable Drug Devices Europe
2024-01-09 - 2024-01-11 | LEONARDO ROYAL HOTEL LONDON TOWER BRIDGE, 45 Prescot Street, London, E1 8GP, United Kingdom
SAE Media Group’s 16th Annual Pre-Filled Syringes and Injectable Drug Devices Conference will return to London in January 2024 to unite leaders from the industry and bring you the latest advances in the combination product drug delivery space.

Year on year, the field of injectable drug delivery has witnessed remarkable progress, marked by advancements in device technology, including smart devices and those designed for large volume drug administration. There has been a shift towards enhancing the patient experience through innovative device design. Moreover, the industry is now moving towards a circular approach for environmental sustainability, incorporating it into device manufacturing and design, as well as device usage. The upcoming conference aims to tackle pressing industry challenges by exploring them through real-world case studies and valuable insights while also considering opportunities for the future.
As part of SAE’s leading Injectable Drug Delivery Series, the 3-day event will comprise of a pre-conference focus day exploring the advances in PFS design for enhanced drug delivery proceeded by a two-day main conference comprising of morning keynote plenaries and parallel afternoon topic streams as detailed below addressing the industry’s hottest topics:

Device Innovations for Large Volume and Highly Viscous Drug Delivery
Sustainability by Design and Material Selection
Primary Packaging Development
Digital Integration for Connected Devices

This event will not only bring you key insights needed to expand and enhance your injectable device portfolio but will also give you the opportunity to network with key players throughout the industry. We hope to welcome you to this must attend event in January 2024!
Benefits of attending:

Engage with pharma, biotech and device developers on the latest trends within the pre-filled syringe and injectable device market
Hear about new technological advances in the delivery of large volume drugs and novel drug products
Understand the latest regulatory requirements from experts surrounding medical devices and digital health
Gain insight into how big pharma is incorporating sustainable approaches into drug device design
Delve into the growing potential of digital health to improve patient experience and treatment

Explore key considerations for material components for the development of primary packaging
To know more visit: www.pre-filled-syringes.com/PharmaJournalist-WL

Gene Therapy Regulatory Affairs Summit
2024-01-23 - 2024-01-25 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
With 2023 welcoming newly FDA-approved gene therapies from BioMarin, Krystal Biotech and Sarepta Therapeutics, many more treatments are hot on their heels for approval, investment is pouring into developing gene therapies and the role of regulatory affairs has never been more important.
As the first ever regulatory affairs forum wholly dedicated to gene therapy, this meeting uniquely unites regulatory bodies and the leading regulatory personnel across big pharma and innovative biotech to discuss the hottest topics, identify industry bottlenecks and offer actionable insights.
Join 80+ industry leaders from 4D Molecular Therapeutics, Advanced Cell & Gene Therapy, Adverum Biotechnologies, Astrazeneca, Bridge Bio, Health Canada, Omega Therapeutics, Opus Genetics, Regeneron Pharmaceuticals, Sangamo Therapeutics, Solid Biosciences, Spark Therapeutics, Ultragenyx Pharmaceutical, and more…
By attending this summit, you will get a chance to:

Understand the nuanced differences and the route to harmonization in global regulation across the EMA, MHRA, FDA & Health Canada
Hone your regulatory intelligence, understand how to use biomarkers as surrogate endpoints and perfect clinical trial strategy for regulatory success
Explore the next steps for specific technologies beyond AAV and novel regulatory route
Hear from the regulators in the Health Canada and the FDA to have your queries clarified

Overcome your CMC hurdles to prove the efficacy, purity & comparability of your compound to avoid later setbacks in poor manufacturing preparation
Don’t miss out on this unrivalled opportunity to inform your trial design, perfect your CMC approach and supercharge your global submission strategy for regulatory success.
Download the full agenda here to see our full speaker faculty, 3-day agenda and audience breakdown: https://ter.li/sgkcr9

3rd mRNA-Based Therapeutics Summit Europe
2024-01-23 - 2024-01-25 | Mecure Hotel MOA Berin, Stephanstraße 41, Berlin, 10559, Germany
250+ mRNA Specialists | 40+ World-Class Speakers | 2 Streams of Content
The 3rd mRNA-Based Therapeutics Summit Europe returns to Berlin this 23rd-25th January to unite European biopharma, to hear from the likes of BioNTech, CureVac, Moderna, Pfizer, Ethris, Sanofi, and regulatory insights for the MHRA and EMA.
Download the full brochure here: https://ter.li/1329up
This is your opportunity to hear the hottest content of the mRNA world, deep diving into two content tracks on Translational Development and CMC, a pre-conference Focus Day on AI RNA Design & Delivery, and three immersive pre-conference workshops.
Join in January to understand the roadmap towards clinical success and regulatory approval, and deliver the promise of better mRNA medicines to patients faster.
Book your place here: https://ter.li/qu2h8f

2nd Next Generation Ophthalmic Drug Delivery Summit
2024-01-30 - 2024-02-01 | The Marker San Francisco, 501 Geary St, San Francisco, CA, 94102, United States
The 2nd Annual Next Generation Ophthalmic Drug Delivery Summit is returning to San Francisco this January to unite 90+ device engineers, biochemists, preclinical and clinical experts as they discuss how they are optimizing longer-lasting and less invasive delivery to the back of the eye to reduce patient concerns and burden on healthcare systems caused by frequent drug administration.
Join 23+ expert speakers from the likes of AbbVie, Boehringer Ingelheim, Bayer, Genentech, Janssen, Novartis, and Clearside Biomedical at the only industry-dedicated event focusing on overcoming key translational challenges of developing and implementing novel delivery technology as they progress their ophthalmic pipelines to the clinic.
To know more visit: https://ter.li/o3pq3n

8th Microbiome Movement - Drug Development Summit Europe
2024-01-30 - 2024-02-01 | Hotel Barceló Sants, Pl. dels Països Catalans, s/n, 08014, Barcelona, 08014, Spain
As Europe’s premiere microbiome conference tightly focused on the development of microbiome-based therapeutics, this is your prime opportunity to expand your microbiome-based drug development capabilities and business potential as we aim to deliver clinical results and ensure therapeutic microbiome approval in Europe.
No matter what stage of development you’re focusing on, this is your one-stop shop for microbiome-based drug development from early discovery to late-phase manufacturing!
What’s New for 2024:

Highlighting early-stage organisations and their novel technologies in our brand-new technology showcase where we welcome Centre for Genomic Regulation, Recolony and Synflora to give quick fire presentations to showcase their work.
Discover our new enabling technologies track to learn more about the exciting artificial intelligence, integrated -omics analysis and improved manufacturing capabilities among the other technologies that are accelerating microbiome-based drug development.
Strengthen your regulatory understanding and enhance decision-making by uncovering global regulations to address updated SoHo frameworks, explore considerations for engineered microbes and consolidate agencies interactions

To know more visit: https://ter.li/zi3xwf

4th Gene Therapy Comparability Summit
2024-02-13 - 2024-02-15 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
As we witness a surge in later-stage clinical trials within the gene therapy industry, the spotlight on comparability has never been brighter. That’s why we’re thrilled to announce the return of the 4th Gene Therapy Comparability Summit, taking place in Boston, MA, February 13-15.

This event is your gateway to uncovering how to implement effective comparability studies to overcome strategic and technical hurdles to expedite more gene therapy approvals.
What to expect at the 2024 meeting:

Gain valuable insights from CSL Behring, Bayer, Ultragenyx, and other industry leaders on the transition to in-house manufacturing, effective variability management, and ensuring consistency across multiple facilities.
Examine Sarepta’s considerations before and after receiving regulatory approval and investigate the distinctions among global regulatory agencies with insights from Novartis, Sarepta, and Adverum.
Strengthen your analytical toolbox and enhance comparability studies through case studies and strategies to reduce variability with AskBio and BioMarin.
Stay ahead of the latest advancements in process development for improved characterization and analysis of AAV-gene therapies, with a focus on minimizing process alterations, featuring contributions from Abbvie and Spark Therapeutics.
Harness strategic insights from cell therapy study design, innovative analytical techniques, and regulatory expertise to enhance your gene therapy comparability protocols, supported by Novartis.

Don’t miss this unparalleled opportunity to stay at the forefront of gene therapy comparability. Join us and gain the knowledge, tools, and connections to secure your gene therapy approval.
Download the full event guide here to view the full expert speaker line up and see who else you will meet: https://ter.li/rrefvp

3rd mRNA Analytical Development Summit
2024-02-13 - 2024-02-15 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
100+ Technical mRNA Specialists | 35+ Expert Speakers
As access to faster and higher-throughput analytical methods becomes increasingly vital, it is critical that we employ superior analytical approaches for mRNA-based therapeutics and vaccines to ensure high quality and effective drugs are approved, whilst adhering to regulatory guidelines.
The 3rd mRNA Analytical Development Summit returns to Boston in February to seek and discuss new guidelines and identify a path forward with tangible best practices to ensure reliable analytical methods are guiding mRNA production, purification and formulation optimization for approval of high quality, compliant mRNA drugs for patients in need.
Download the three day program here: https://ter.li/pi54tj
100+ Heads, Directors and Senior Scientists of Analytical Development, Quality Control, CMC and Regulatory Affairs will deep dive into analytical development techniques and challenges within mRNA drug product and drug substance, eager to glean insights into future analytical methods to safeguard regulatory submissions in 2024 and beyond.
Join them and register your place here: https://ter.li/d6nqe3

6th Annual CRISPR AgBio Congress
2024-02-20 - 2024-02-22 | Sheraton Raleigh Hotel, 421 South Salisbury St, Raleigh, NC, 27601, United States
The 6th Annual CRISPR AgBio Congress is back on February 20-22, 2024 (Raleigh, NC). The dedicated congress that unites industry stakeholders across Agbiotech, big seed, distributors, and investors, to assess this new regulatory terrain, examine recent scientific breakthroughs, and strategize the journey of CRISPR products from editing to delivery, field to shelf.
Discover the full program here.
Back for its 6th edition, join the likes of the Pairwise CEO, and advisors at USDA and EPA as we:

Discover the latest on the global and US regulatory landscape, uncover what’s new for standardizing approval processes, and tackle regulatory compliance for your products
Uncover novel gene editing tools and CRISPR technologies, AI, Cas-12, and CRISPR-enabled breeding and trait discovery tools to address unmet agricultural challenges
Explore CRISPR product commercialization and effective market targeting strategies for rapid adoption
Transform agriculture with sustainable crop solutions: explore alternative fuels and precision breeding for enhanced crop sustainability
Unpick how to enhance the adaptability, productivity, and nutrition of orphan and non-model crops such as potatoes, and strawberries to accelerate breeding and cut costs

View your copy here to find the jam-packed agenda, with exclusive case studies led by industry giants and regulatory bodies to help you commercialize regulatory-approved gene-edited agriculture products.
Join 80+ C-level leaders, researcher heads, Molecular Biologists, Regulatory Experts, and Product Developers from major seed companies, innovative Agbiotechs, influential academic institutions, and regulatory bodies and be part of the conversation in 2024.
Here’s what past attendees had to say:
“Great quality of presentations and coherent style of participants: scientists with key roles in their company and key relevant academic researchers” – Chief Executive Officer, Meiogenx
“The arrangements for the conference, quality of speakers, and novel ways to encourage networking were great” – Senior Director, Yield10 Bioscience

2nd Viral Vector Process Development & Manufacturing
2024-02-20 - 2024-02-22 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
Viral Vector Process Development & Manufacturing Summit
Create Qualitative, Accessible Treatments for Patients
Following Ring Therapeutics’ injection of $86.5m to enhance novel viral vector capabilities, and BMS’s viral vector facility coming online, the viral vector market is forecasted to reach $12.8bn – not only in cell and gene therapies but also viral-vector-based vaccines and immunotherapies.

With the FDA’s fast-evolving quality assessment and lack of standard guidance, and the continued challenge of viral vector recovery yield and purity, the 2nd Viral Vector Process Development & Manufacturing Summit is your must-attend meeting in 2024 to help answer your burning questions to enhance process intensification capabilities while meeting regulatory agencies’ expectations.
In collaboration with Sarepta, Ultragenyx, Affinia Therapeutics, and UCB, we will unite 130+ pioneering viral vector up- and downstream process engineers, MSAT, CMC to tackle these challenges together. This is your definitive community to seek help from industry pioneers to expedite scale-up, tech transfer, and speed-to-clinic. Returning to Boston in February, we are proud to expand the program into 2 tracks of content as the only industry-led, end-to-end summit to align with your needs:

Downstream process intensification, including purification, to improve recovery and yield
Purity assessment to uphold GMP and product quality assessment
Deep dive into upstream process development and cell line in relation to your viral vectors, and assess platforming strategy
Rapid scale-up with robust analytical capabilities and improve your full:empty capsid ratio and reduce COGs
Meet and evaluate solution providers and viral vector CDMOs, including Lonza, Chromatan, Teknova, and Genezen, to forge long-term relationships, ensuring tech transfer readiness

It’s worth clearing 3 days out of your office and joining this summit to leverage novel platform technologies such as continuous processing to improve viral vector manufacturing!
To know more visit: https://ter.li/fvlk3e

3rd Next-Generation Conjugates Summit
2024-02-26 - 2024-02-28 | Hotel Commonwealth, 500 Commonwealth Avenue, Boston, MA, 02215, United States
From Bristol Myers Squibb expanding their cardiovascular partnership with Avidity Biosciences’ antibody-oligonucleotide conjugate technology, to Nurix and Seagen collaborating on a targeted protein degradation conjugate, there is now a staggering amount of investment and collaboration in the novel conjugates space.
As highlighted above, drug developers are pushing the boundaries of traditional ADCs by designing and developing novel targeting formats and payloads. Whilst the likes of VincerX Pharma, Dyne Therapeuitcs and Alnylam are now awaiting clinical validation, and others continue to innovate in conjugate design, it is an exciting time for the next-generation conjugates field.

Covering case-study led presentations on novel design concepts, key translational and clinical development challenges, and addressing challenging CMC roadblocks, the Next-Generation Conjugates Summit is your only event uniting developers of a wide array of novel formats and payloads, with conjugate modality types including antibody-oligonucleotide conjugates, fragment-drug conjugates, Targeted Radiopharmaceutical Conjugates, small molecule-drug conjugates, bispecific-drug conjugates and more!
This is the only event to unite 100+ drug developers from companies of different modality types that would not normally come together, so make sure to join likeminded conjugate developers to learn, collaborate and innovate and expand on the potential of conjugate drugs.
Learn more here: https://ter.li/q5wf9x

7th CAR-TCR Summit Europe
2024-02-27 - 2024-02-29 | ExCeL London, Royal Victoria Dock, 1 Western Gateway, London, E16 1XL, United Kingdom
Cell therapy continues to transform the oncology field, and this year has also seen the translation of cell therapies’ curative potential into the autoimmune space.
Providing your team with exclusive access to cutting-edge advances across pre-clinical platforms, clinical advances, and streamlined manufacturing, the 7th CAR-TCR Summit Europe is your must-attend forum to stay at the forefront of these innovations.
300+ industry experts will brainstorm enhancing target discovery, optimizing durability of response and identifying biomarkers to support recruitment, automating production, and accelerating analytical processes to reduce operational costs and turnaround times.
With a new Biopharma & Investors Evening, a new C-Level Think Tank, new speakers and data from Mnemo Therpaeutics, Cellectis, Bambino Gesu Hospital and more, can your team afford to miss out?
To know more visit: https://ter.li/6vgioi

6th Bacteriophage Therapy Summit
2024-02-27 - 2024-02-29 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The Bacteriophage Therapy Summit is the only global platform for industry-dominated phage drug developers. Actively engage with the likes of Merck, Pfizer, SNIPR Biome, Locus Biosciences, Phiogen, AMR Action Fund and 90+ phage experts to demonstrate positive clinical data and patient outcomes.
Take advantage of this unique opportunity to be a part of the dialogue, meet phage leaders, large pharma, and venture capitalists to gain practical takeaways, and demonstrate the clinical utility of your bacteriophage to form meaningful partnerships.
Join us for 3 days of unmissable content, and accelerate your bacteriophage research into clinical, meaningful and commercially viable therapies.
Check out the full event guide now: https://ter.li/jig8n0

DNA Process Development & Manufacturing Summit
2024-03-05 - 2024-03-07 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
With the cell and gene therapy industry surging, rapid advances in mRNA-based therapies, and the advent of DNA vaccines, the demand for quality DNA as a critical starting and therapeutic material has skyrocketed in recent years.
The DNA Process Development & Manufacturing Summit is the only industry-dedicated forum to focus on topics such as DNA construct design, sequencing technology, and scaling production for preclinical and clinical programs, helping to expedited IND submissions and approvals.
Download the official event guide here: https://ter.li/9hpxb2
Innovative biopharma including BioNTech, Genentech, AskBio, Pfizer, Roche, Sanofi and more will unite in Boston to build the ultimate roadmap from plasmids through to synthetic and novel DNA innovations, helping you advance your manufacturing capabilities for high quality therapeutics and vaccines.
Register your place here: https://ter.li/8kdoo7

14th World ADC London 2024
2024-03-12 - 2024-03-15 | ExCeL London, Royal Victoria Dock, 1 Western Gateway, London, E16 1XL, United Kingdom
We find ourselves at the cutting edge of oncology innovation, with the ADC field booming with excitement due to the constant eflux of clinical progress and a plethora of high-value collaborations.
As such the 14th World ADC London 2024 returns this March as a crucial touchpoint for all antibody drug conjugate developers across Europe.
This meeting is the place where innovation meets collaboration to drive antibody-drug conjugates forward and transform cancer therapy as we know it. Uniting 600+ industry experts and ADC newcomers, this is a conversation you can’t afford to miss.
Take a look at the full agenda here.
Embark on a knowledge-rich adventure as we explore the intricate nuances of ADC development. From the initial stages of target identification and antibody engineering to the complexities of clinical trials and CMC strategies to navigating commercialisation, expect to leave this event with a comprehensive understanding of the entire ADC lifecycle.
Here are some of the leading minds sharing translatable lessons to advance your pipeline including:

Astrid Clarke, Director, Head of Early-Stage IND to Medicine Research,Seagen
Colm Reddington, Director- Global Regulatory, Chemistry, Manufacturing & Control, AstraZeneca
Daniel Milano, Senior Director, Process Development, ImmunoGen
Dhiraj Gambhire, Executive Director – Global Clinical Lead, Enhertu, Breast & Medical, Daiichi Sankyo
Emmett Scmidtt, Vice President, Lead External- Collaborations Project Team Global Clinical Development, Merck & Co
Gerold Meindhart, Vice President, Asset & Portfolio Management, Daiichi Sankyo
Ian Andrews, Senior Manager, Strategic External Development, GlaxoSmithKline
Kurt Pike, Senior Director, External Innovation, Janssen
Larisa Stone, Clinical Development Director, Gilead
Lolke deHaan, Vice President, Toxicology, ADC Therapeutics
Mike Liao, Global Clinical Pharmacology Lead, Genentech
Venkatesh Pilla Reddy, Senior Director, Global PKPD & Pharmacometrics, Eli Lilly

See the full speaker faculty and session details here.
Whether you are pioneering ADC discoveries, accelerating your conjugate through preclinical and clinical development, or optimising your CMC efforts, this is your chance to ahead of the curve with the high-quality and invaluable guidance of the supportive ADC community.

7th Antigen-Specific Immune Tolerance Drug Development Summit
2024-03-18 - 2024-03-20 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
Returning for the seventh year, the 7th Antigen-Specific Immune Tolerance Summit (March 18 – 20, 2024 | Boston, MA) will lean into the industry’s key challenges from details of T-cell assays in preclinical and larger clinical studies; to pioneering CAR-Treg, mRNA-LNP, biologic, peptide, approaches and updates on proof-of-concept and ongoing clinical programs. This is the highest value meeting on the immune tolerance community’s conference calendar.
This is your comprehensive guide to define your pipeline and therapeutic development strategy for 2023, delve into your opportunity to create tolerizing, curative, strategies for autoimmunity, and tap into your tolerance strategy to tackle immunogenicity and transform the biologic landscape. Network with large pharma scouts, industry super-giants, and biotech pioneers to build meaningful partnerships and gather insights beyond the literature.
Expect to be involved in interactive discussions on:

Tackle antigen-selection and deepen your understanding of the role of T-cells, B-cells and T-regs in immune tolerance evaluate strategies and technologies in complex heterogenous disease settings with COUR Pharmaceuticals and Pfizer.
Build the biomarker toolbox and engage in discussions around the true markers of ‘tolerance’ for practical tolerance strategies and markers for determinants of efficacy, patient selection, and therapeutic durability with Takeda, University of Pittsburgh, Imcyse, and Anokion
Assess toxicity and durability of tolerance therapeutics using preclinical models to inform the frequency of administration and the persistence or loss of tolerance over time with Toleranzia and University of Helsinki
Evaluate delivery technologies and novel approaches including CAR-Treg, mRNA-LNP, biologics, and more to propel tolerizing therapies through proof-of-concept to the clinic with Sonoma, Moderna, and Integrated Nanotherapeutics
Harness mechanistic models and autoimmune disease models to highlight efficacious tolerance induction across diseases including Celiac, Type 1 Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, and more with GRO Bioscience, RheumaGen, NexImmune, and Parvus Therapeutics

Join 110+ autoimmune and immunologist scientists, corporate strategists, and large pharma scouts at this timely and comprehensive summit set to unite the immune tolerance field. From innovative, start-up biotechs to big pharma super giants, this is your unique opportunity to discuss advancing efficacious antigen- and drug-specific tolerance approaches to patients in need.
Download the full agenda here to see our full speaker faculty, 3-day agenda and audience breakdown: https://ter.li/7teig8
